Note 18 - Segments (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	For the years ended December 31,
(In thousands)	2023			2022			2021
Revenue from services:
Pharmaceutical	$	—		$	—		$	—
Diagnostics		515,275			755,630			1,607,106
Corporate		—			—			—
	$	515,275		$	755,630		$	1,607,106
Revenue from products:
Pharmaceutical	$	167,557		$	142,845		$	141,770
Diagnostics		—			—			—
Corporate		—			—			—
	$	167,557		$	142,845		$	141,770
Revenue from transfer of intellectual property and other:
Pharmaceutical	$	180,663		$	105,721		$	25,842
Diagnostics		—			—			—
Corporate		—			—			—
	$	180,663		$	105,721		$	25,842
Operating income (loss):
Pharmaceutical	$	41,184		$	(12,961	)	$	(19,051	)
Diagnostics		(155,596	)		(173,652	)		98,067
Corporate		(42,609	)		(39,640	)		(60,266	)
	$	(157,021	)	$	(226,253	)	$	18,750
Depreciation and amortization:
Pharmaceutical	$	71,548		$	68,618		$	26,427
Diagnostics		33,749			40,037			52,289
Corporate		—			—			—
	$	105,297		$	108,655		$	78,716
Loss from investment in investees:
Pharmaceutical	$	(107	)	$	(383	)	$	(629	)
Diagnostics		—			—			—
Corporate		—			—			—
	$	(107	)	$	(383	)	$	(629	)
Revenues:
U.S.	$	597,822		$	783,207		$	1,640,354
Ireland		141,465			117,214			32,809
Chile		68,491			62,044			63,798
Spain		23,517			22,477			22,682
Israel		9,738			3,845			3,563
Mexico		20,216			14,546			11,005
Other		2,246			863			507
	$	863,495		$	1,004,196		$	1,774,718

Reconciliation of Assets from Segment to Consolidated [Table Text Block]

(In thousands)	December 31, 2023		December 31, 2022
Assets:
Pharmaceutical	$	1,331,764	$	1,322,531
Diagnostics		630,753		690,504
Corporate		49,181		154,224
	$	2,011,698	$	2,167,259
Goodwill:
Pharmaceutical	$	315,235	$	312,826
Diagnostics		283,025		283,025
	$	598,260	$	595,851

Long-Lived Assets by Geographic Areas [Table Text Block]

(In thousands)	December 31, 2023		December 31, 2022
PP&E:
U.S.	$	39,852	$	52,795
Foreign		35,577		30,084
Total	$	75,429	$	82,879